A promising preclinical model for TERT promoter mutation in glioblastoma.
作者信息
Huse Jason T
机构信息
Department of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
出版信息
Neuro Oncol. 2022 Dec 1;24(12):2076-2077. doi: 10.1093/neuonc/noac167.
Abstract
摘要
相似文献
1
A promising preclinical model for TERT promoter mutation in glioblastoma.一种用于胶质母细胞瘤中TERT启动子突变的有前景的临床前模型。
Neuro Oncol. 2022 Dec 1;24(12):2076-2077. doi: 10.1093/neuonc/noac167.
2
Programmable base editing of mutated TERT promoter inhibits brain tumour growth.可编程碱基编辑突变 TERT 启动子抑制脑肿瘤生长。
Nat Cell Biol. 2020 Mar;22(3):282-288. doi: 10.1038/s41556-020-0471-6. Epub 2020 Feb 17.
3
Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.β1L 异构体的 GABP 破坏以 TERT 启动子突变依赖性方式逆转胶质母细胞瘤复制性永生。
Cancer Cell. 2018 Sep 10;34(3):513-528.e8. doi: 10.1016/j.ccell.2018.08.003.
4
Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.胶质母细胞瘤中TERT启动子激活突变的预后质量：与rs2853669多态性及诊断时患者年龄的相互作用
Neuro Oncol. 2015 Sep;17(9):1231-40. doi: 10.1093/neuonc/nov010. Epub 2015 Feb 13.
5
Telomerase as a therapeutic target in glioblastoma.端粒酶作为胶质母细胞瘤的治疗靶点。
Neuro Oncol. 2021 Dec 1;23(12):2004-2013. doi: 10.1093/neuonc/noab203.
6
High incidence of TERT mutation in brain tumor cell lines.脑肿瘤细胞系中TERT突变的高发生率。
Brain Tumor Pathol. 2016 Jul;33(3):222-7. doi: 10.1007/s10014-016-0257-5. Epub 2016 Mar 9.
7
When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.当终点成为起点：端粒酶靶向治疗胶质母细胞瘤。
Curr Neurol Neurosci Rep. 2018 Mar 10;18(4):15. doi: 10.1007/s11910-018-0825-7.
8
The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.TERT 启动子突变状态和 MGMT 启动子甲基化状态，结合 MRI 衍生的和临床特征的二分法，可预测成人原发性胶质母细胞瘤的生存。
Cancer Med. 2018 Aug;7(8):3704-3712. doi: 10.1002/cam4.1666. Epub 2018 Jul 9.
9
New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma.新的体细胞 TERT 启动子变异增强胶质母细胞瘤中的端粒酶活性。
Acta Neuropathol Commun. 2020 Aug 25;8(1):145. doi: 10.1186/s40478-020-01022-4.
10
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.TERT 启动子野生型/IDH 野生型胶质母细胞瘤的基因组景观。
Nat Commun. 2018 May 25;9(1):2087. doi: 10.1038/s41467-018-04448-6.
本文引用的文献
1
TERT promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening in vivo.神经祖细胞中的 TERT 启动子 C228T 突变赋予了体内端粒缩短后的生长优势。
Neuro Oncol. 2022 Dec 1;24(12):2063-2075. doi: 10.1093/neuonc/noac080.
2
Current trends in mouse models of glioblastoma.胶质母细胞瘤小鼠模型的当前趋势。
J Neurooncol. 2017 Dec;135(3):423-432. doi: 10.1007/s11060-017-2626-2. Epub 2017 Oct 20.
3
Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease.敌友难辨？端粒酶作为癌症和心血管疾病的药物靶点
Pharmacol Res. 2016 Sep;111:422-433. doi: 10.1016/j.phrs.2016.07.003. Epub 2016 Jul 6.
4
Understanding TERT Promoter Mutations: A Common Path to Immortality.了解端粒酶逆转录酶启动子突变：通往不朽的常见途径。
Mol Cancer Res. 2016 Apr;14(4):315-23. doi: 10.1158/1541-7786.MCR-16-0003. Epub 2016 Mar 3.
5
Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.癌症。转录因子GABP在癌症中选择性地结合并激活突变的端粒酶逆转录酶（TERT）启动子。
Science. 2015 May 29;348(6238):1036-9. doi: 10.1126/science.aab0015. Epub 2015 May 14.
6
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.TERT 启动子突变在神经胶质瘤和一小部分源自自我更新率低的细胞的肿瘤中频繁发生。
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6. doi: 10.1073/pnas.1303607110. Epub 2013 Mar 25.
Zotero 插件